Literature DB >> 29305960

Antibiotic susceptibilities of livestock isolates of leptospira.

Geoffroy Liegeon1, Tristan Delory2, Mathieu Picardeau3.   

Abstract

Leptospirosis is the most common zoonotic disease and is endemic worldwide. The antibiotic susceptibilities of Leptospira strains isolated from both humans and animals are poorly documented. This issue is particularly important for isolates from food-producing animals which are regularly exposed to antibiotic treatments. This study assessed the susceptibility of 35 leptospira strains isolated from food-producing animals of diverse geographical origins between 1936 and 2016 to the antimicrobial agents used most commonly in animals. A broth microdilution method was used to determine the susceptibilities of Leptospira strains isolated from livestock to 11 antibiotics. All isolates were susceptible to penicillin, amoxicillin, clavulanate, cephalexin, ceftriaxone, doxycycline, tetracycline, streptomycin, enrofloxacin and spectinomycin, but not polymyxin [minimum inhibitory concentration (MIC) ≥ 4 μg/L]. For tetracycline and doxycycline, the MIC was significantly higher for the recent isolates from Sardinia, Italy than for the other isolates. Antimicrobial susceptibilities were also determined with 10- and 100-fold higher inocula. High inocula significantly diminished the antibacterial effect by at least 10-fold for enrofloxacin (MIC ≥256 μg/L), streptomycin (MIC ≥16 μg/L) and tetracycline (MIC ≥32 μg/L), suggesting selection of resistant strains for high inocula. These findings contribute to the assessment of whether certain antibiotics are potentially useful for the treatment of leptospirosis, and point out the risk of failure for some antibiotics during infection with a high inoculum in both animals and humans. This study strengthens the need to detect and prevent the emergence of antimicrobial resistance of this major emerging zoonotic pathogen.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotic susceptibility; High inoculum; Leptospira; Leptospirosis; Livestock; MIC

Mesh:

Substances:

Year:  2018        PMID: 29305960     DOI: 10.1016/j.ijantimicag.2017.12.024

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Prevalence of leptospirosis among patients attending renal and general outpatient clinics in Mulago Hospital, Kampala, Uganda.

Authors:  Rogers Wambi; William Worodria; James Muleme; Siya Aggrey; Lawrence Mugisha
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

2.  Reduced susceptibility in leptospiral strains of bovine origin might impair antibiotic therapy.

Authors:  L Correia; A P Loureiro; W Lilenbaum
Journal:  Epidemiol Infect       Date:  2018-09-04       Impact factor: 2.451

Review 3.  Insight into the Epidemiology of Leptospirosis: A Review of Leptospira Isolations from "Unconventional" Hosts.

Authors:  Giovanni Cilia; Fabrizio Bertelloni; Sara Albini; Filippo Fratini
Journal:  Animals (Basel)       Date:  2021-01-14       Impact factor: 2.752

4.  Isolation of Leptospira serovar Pomona from a crested porcupine (Hystrix cristata, L., 1758).

Authors:  Giovanni Cilia; Fabrizio Bertelloni; Francesca Coppola; Barbara Turchi; Claudia Biliotti; Alessandro Poli; Francesca Parisi; Antonio Felicioli; Domenico Cerri; Filippo Fratini
Journal:  Vet Med Sci       Date:  2020-06-17

5.  Determination of minimum inhibitory and minimum bactericidal concentrations of Brazilian strains of Leptospira spp. for streptomycin sulphate.

Authors:  Bruno Ribeiro Rocha; Gabriel Mendes de Souza Martins; Breno Cayeiro Cruz; Walter Lilenbaum
Journal:  Epidemiol Infect       Date:  2020-09-25       Impact factor: 2.451

6.  In Vitro Anti-Leptospiral Activity of Phyllanthus amarus Extracts and Their Combinations with Antibiotics.

Authors:  Che Ain Munirah Ismail; Zakuan Zainy Deris; Ruzilawati Abu Bakar; Nabilah Ismail
Journal:  Int J Environ Res Public Health       Date:  2021-03-10       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.